Pre-made Envafolimab biosimilar ( Single Domain Variable Fragment;H, anti-PDL1 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-188
Anti-PDL1 therapeutic antibody (Pre-made Envafolimab biosimilar,Single Domain Variable Fragment;H) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Envafolimab is a novel, single-domain PD-L1 antibody that is administered by subcutaneous injection without the need for an adjuvant.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-PDL1 therapeutic antibody (Pre-made Envafolimab biosimilar,Single Domain Variable Fragment;H)|
|Format||Single Domain Variable Fragment;H|
|Highest_Clin_Trial (Jan '20)||Preregistration|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Alphamab;3D Medicines;Sun Yat-Sen University|
|Conditions Active||Biliary cancer;Breast cancer;Solid tumours;Gastric cancer;Gastrointestinal cancer;Hepatitis B;Malignant fibrous histiocytoma;Soft tissue sarcoma|